ScreenerHero

YARWYarrow Bioscience Inc. Common Stock

NAS · US · Healthcare · Biotechnology · yarrowbioscience.com
36.42USD-10.28%Mkt Cap: 97.25M $P/E: —

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap97.25M $
Enterprise Value197.60M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-283.98M $
Revenue/Share—
Last Price36.42 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-23.15
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B—
EPS (TTM)—
EPS (Forward)-1.65
52W Range
14.0568% of range46.95
52W High46.95 USD
52W Low14.05 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE—
ROA—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF560.00K $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-18.67M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio1.40
Quick Ratio1.40
Book Value/Sh—
Cash/Share6.126 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div DateJul 24, 2026
Pay DateJul 23, 2026
Splits
Last Split1:50
Split DateJul 27, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)57.00 USD
Upside (mean)+56.5%
Target Range56.00 USD – 58.00 USD
$56.00+56.5% to mean$58.00
# Analysts2
Ownership
Shares Out.2.67M
Float1.75M
Insiders4.48%
Institutions60.77%
Short Interest
Short Ratio0.6d
Short % Out.0.47%
Shares Short12.58K
Technical
SMA 5035.83 (+1.7%)
SMA 20029.94 (+21.6%)
Beta2.08
S&P 52W Chg18.16%
Avg Vol (30d)39.74K
Avg Vol (10d)17.05K
Technical Indicators
RSI (14)46.2
MACD1.5052
MACD Signal1.6405
MACD Hist.-0.1353
BB Upper49.38 USD
BB Middle37.51 USD
BB Lower25.65 USD
BB Width63.27%
ATR (14)3.372 USD
Vol Ratio (20d)1.02x